NASDAQ
MASS

908 Devices Inc

Medical Devices
Healthcare

Prices are adjusted according to historical splits.

908 Devices Inc Stock Price

Vitals

Today's Low:
$6.22
Today's High:
$6.47
Open Price:
$6.45
52W Low:
$5.69
52W High:
$18.02
Prev. Close:
$6.47
Volume:
106054

Company Statistics

Market Cap.:
$226.99 million
Book Value:
5.397
Revenue TTM:
$49.02 million
Operating Margin TTM:
-84.08%
Gross Profit TTM:
$26.02 million
Profit Margin:
-77.37%
Return on Assets TTM:
-11.25%
Return on Equity TTM:
-20.2%

Company Profile

908 Devices Inc had its IPO on 2020-12-18 under the ticker symbol MASS.

The company operates in the Healthcare sector and Medical Devices industry. 908 Devices Inc has a staff strength of 227 employees.

Stock update

Shares of 908 Devices Inc opened at $6.45 at the start of the last trading session i.e. 2023-09-12.

The stocks traded within a range of $6.22 - $6.47, and closed at $6.34.

This is a -2.01% slip from the previous day's closing price.

A total volume of 106,054 shares were traded at the close of the day’s session.

In the last one week, shares of 908 Devices Inc have slipped by -10.83%.

908 Devices Inc's Key Ratios

908 Devices Inc has a market cap of $226.99 million, indicating a price to book ratio of 1.4363 and a price to sales ratio of 5.3919.

In the last 12-months 908 Devices Inc’s revenue was $49.02 million with a gross profit of $26.02 million and an EBITDA of $-38942000. The EBITDA ratio measures 908 Devices Inc's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, 908 Devices Inc’s operating margin was -84.08% while its return on assets stood at -11.25% with a return of equity of -20.2%.

In Q2, 908 Devices Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 8.9%.

908 Devices Inc’s PE and PEG Ratio

Forward PE
0
Trailing PE
0
PEG

Its diluted EPS in the last 12-months stands at $-1.12 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into 908 Devices Inc’s profitability.

908 Devices Inc stock is trading at a EV to sales ratio of 2.1233 and a EV to EBITDA ratio of -4.2008. Its price to sales ratio in the trailing 12-months stood at 5.3919.

908 Devices Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets
$210.83 million
Total Liabilities
$20.19 million
Operating Cash Flow
$-19936000.00
Capital Expenditure
$320000
Dividend Payout Ratio
0%

908 Devices Inc ended 2024 with $210.83 million in total assets and $0 in total liabilities. Its intangible assets were valued at $210.83 million while shareholder equity stood at $174.46 million.

908 Devices Inc ended 2024 with $2.59 million in deferred long-term liabilities, $20.19 million in other current liabilities, 32000.00 in common stock, $-156078000.00 in retained earnings and $10.19 million in goodwill. Its cash balance stood at $133.00 million and cash and short-term investments were $152.69 million. The company’s total short-term debt was $1,860,000 while long-term debt stood at $0.

908 Devices Inc’s total current assets stands at $181.08 million while long-term investments were $0 and short-term investments were $19.69 million. Its net receivables were $10.31 million compared to accounts payable of $1.49 million and inventory worth $14.14 million.

In 2024, 908 Devices Inc's operating cash flow was $-19936000.00 while its capital expenditure stood at $320000.

Comparatively, 908 Devices Inc paid $0 in dividends in 2024.

Other key metrics

Current Trading Price
$6.34
52-Week High
$18.02
52-Week Low
$5.69
Analyst Target Price
$17

908 Devices Inc stock is currently trading at $6.34 per share. It touched a 52-week high of $18.02 and a 52-week low of $18.02. Analysts tracking the stock have a 12-month average target price of $17.

Its 50-day moving average was $7.1 and 200-day moving average was $8.18 The short ratio stood at 6.51 indicating a short percent outstanding of 0%.

Around 800.4% of the company’s stock are held by insiders while 8653.2% are held by institutions.

Frequently Asked Questions About 908 Devices Inc

The stock symbol (also called stock or share ticker) of 908 Devices Inc is MASS

The IPO of 908 Devices Inc took place on 2020-12-18

Similar Industry Stocks (Medical Devices)

Last Price
Chg
Chg%
$16.98
0.04
+0.24%
$0
-0
-2.86%
$2623.25
-194.3
-6.9%
$21.24
0.11
+0.51%
$0.4
0.04
+11.11%
$30.5
-0.4
-1.29%
$4.7
0.2
+4.44%
HMT LTD. (HMT)
$35.15
-1.85
-5%
$505.25
-27.6
-5.18%

Most Active

Last Price
Chg
Chg%
Amyris Inc (AMRS)
$0.14
0.07
+100%
$0.12
0.04
+45.29%
$0.96
0.05
+5.4%
$1.34
-0.35
-20.71%
Humbl Inc (HMBL)
$0
0
0%

Top Gainers

Last Price
Chg
Chg%
$0
0
+172200%
$0
0
+51200%
$283
280.03
+9428.62%
$11.2
10.57
+1667.68%
Latch Inc (LTCHW)
$0.01
-0.03
+1550%

Top Losers

Last Price
Chg
Chg%
$0.19
-123.15
-99.85%
$0
-0.11
-99.55%
$0
-0
-97.96%
$0
-0.01
-93.94%
$0.01
-0.06
-92.24%

About

908 Devices Inc., a commercial-stage technology company, provides various purpose-built handheld and desktop mass spectrometry (Mass Spec) devices to interrogate unknown and invisible materials in life sciences research, bioprocessing, industrial biotech, forensics, and adjacent markets. The company’s products include MX908, a handheld, battery-powered, and Mass Spec device that is designed for rapid analysis of gas, liquid, and solid materials of unknown identity; Rebel, a small desktop analyzer that provides real-time information on the extracellular environment in bioprocesses; Maven and Trace C2, an online device for bioprocess monitoring and control; and ZipChip solution, a plug-and-play, high-resolution separation platform that optimizes Mass Spec sample analysis. It operates in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. 908 Devices Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.

Address

645 Summer Street, Boston, MA, United States, 02210